Stay updated with breaking news from Xianjun Yu. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes...
HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 -- HUTCHMED Limited today announces that new and updated data from several studies of compounds discovered by HUTCHMED will be...
Investegate announcements from HUTCHMED Presentations at 2024 ASCO Annual Meeting
Title: A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations. Lead Author Session: Abstract Number: About Savolitinib Savolitinib is an oral, potent, and highly selective small molecule inhibitor of MET, a receptor tyrosine kinase which has been shown to function abnormally in many types of solid tumors promoting tumor growth, angiogenesis, and metastasis. Savolitinib has been studied in over 1,100 patients to date. In clinical studies, it has shown promising clinical efficacy i...